NPM1 and acute myeloid leukemia: A clinical trial conducted by the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) is currently investigating the use of VEN + AZA specifically as bridge to transplant in NPM1-mutated AML with MRD persistence or molecular disease recurrence (NCT04867928).